高甘油三酯血症治疗药物市场（2026—2031）
高甘油三酯血症治疗药物市场规模预计由2026年的156.4亿美元增至2031年的208.5亿美元，预测期复合年增长率为5.93%。北美是当前最大市场，亚太地区增长最快。
市场研究正文
规模、增长、细分、驱动因素与关键问题
当前质量分 100.00，审核状态 accepted。结构化字段已按 RoboInd 内容层级组织。
核心结论
高甘油三酯血症治疗药物市场规模预计由2026年的156.4亿美元增至2031年的208.5亿美元，预测期复合年增长率为5.93%。北美是当前最大市场，亚太地区增长最快。
市场走势
结构化指标
| 指标 | 年份 | 数值 | 性质 |
|---|---|---|---|
| 复合年增长率 | 2031 | 5.93% | 机构预测 |
| 市场规模 | 2026 | USD 15.64 billion | 机构预测 |
| 市场规模 | 2031 | USD 20.85 billion | 机构预测 |
细分市场份额
市场结构
| 维度 | 细分项 | 年份 | 份额 |
|---|---|---|---|
| disease_type | secondary hypertriglyceridemia | 2025 | 46.800% |
| distribution_channel | retail pharmacies | 2025 | 42.500% |
| drug_class | statins | 2025 | 38.600% |
| geography | North America | 2025 | 39.400% |
| route_of_administration | oral therapies | 2025 | 81.200% |
关键结论
- disease_type 维度中，secondary hypertriglyceridemia 在 2025 年的公开份额为 46.8%。
- distribution_channel 维度中，retail pharmacies 在 2025 年的公开份额为 42.5%。
- drug_class 维度中，statins 在 2025 年的公开份额为 38.6%。
- geography 维度中，North America 在 2025 年的公开份额为 39.4%。
- route_of_administration 维度中，oral therapies 在 2025 年的公开份额为 81.2%。
主要参与者
- Sanofi
- Amarin Corporation plc
- AbbVie Inc.
- Hikma Pharmaceuticals PLC
- Ionis Pharmaceuticals, Inc.
增长驱动因素
| 因素 | 影响 CAGR | 地区相关性 | 影响周期 |
|---|---|---|---|
| Increasing Prevalence of Obesity, Diabetes, and Metabolic Syndrome | +1.200% | Global, amplified in North America, South Asia, and Southeast Asia | Medium term (2-4 years) |
| Growing Recognition of Residual Cardiovascular Risk | +0.900% | North America and Europe, with spillover to Asia-Pacific and GCC | Medium term (2-4 years) |
| Regulatory Validation of ApoC-III-Targeted Therapies | +1.500% | North America, with the European Union trajectory lagging 12.00-24.00 months | Short term (≤ 2 years) |
| Longer Dosing Intervals Improving Treatment Persistence | +0.600% | North America and Europe | Short term (≤ 2 years) |
| Genetic Phenotyping Expanding Identification of Familial Chylomicronemia | +0.400% | North America, the United Kingdom, and core European Union markets | Long term (≥ 4 years) |
| Convergence of Triglyceride, Liver Fat, and Glycemic Management | +0.700% | Global, with the greatest clinical integration in Asia-Pacific and North America | Long term (≥ 4 years) |
市场制约因素
| 因素 | 影响 CAGR | 地区相关性 | 影响周期 |
|---|---|---|---|
| Lifestyle Modification as a Low-Cost Treatment Alternative | -0.400% | Global, especially Asia-Pacific and South America | Medium term (2-4 years) |
| Reimbursement Restrictions and High Cost of Novel Therapies | -0.800% | North America and Europe, with spillover to Asia-Pacific | Short term (≤ 2 years) |
| Requirement for Combination Lipid Management Following ApoC-III Inhibition | -0.300% | Global | Medium term (2-4 years) |
| Safety Monitoring and Uncertainty of Long-Term Cardiovascular Outcomes | -0.500% | Global, with the greatest prescriber hesitation in Europe and Japan | Long term (≥ 4 years) |
报告关注的关键问题
What is driving demand for hypertriglyceridemia therapeutics?
Rising obesity, diabetes, metabolic syndrome, and related liver disease are increasing the number of patients who need clinical management.
Which disease type holds the largest share?
Secondary hypertriglyceridemia held 46.80% of revenue in 2025 because it is associated with common metabolic and lifestyle-related conditions.
Which treatment class is growing the fastest?
ApoC-III-targeted therapies are projected to grow at a 24.80% CAGR through 2031, supported by recent FDA approvals.
Why are RNA-based therapies important for familial chylomicronemia syndrome?
Olezarsen and plozasiran offer targeted treatment options for this rare disorder and support greater genetic testing activity.
Why are specialty pharmacies becoming more important?
Specialty pharmacies are projected to grow at a 10.20% CAGR because high-cost injectable therapies need authorization, monitoring, and coordinated dispensing.
How concentrated is the competitive environment?
The generic tier includes many manufacturers, while a small group of innovators leads specialty RNA-based development.
市场概览
- 增长最快市场：亚太地区
- 最大市场：北美
- 市场集中度：中等
查看来源：Mordor Intelligence